Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD
70.11
-1.30 (-1.82%)
At close: Mar 28, 2024, 4:00 PM
71.54
+1.43 (2.04%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Total Valuation

Cytokinetics has a market cap or net worth of $7.36 billion. The enterprise value is $7.50 billion.

Market Cap 7.36B
Enterprise Value 7.50B

Important Dates

The next estimated earnings date is Thursday, May 2, 2024, after market close.

Earnings Date May 2, 2024
Ex-Dividend Date n/a

Share Statistics

Cytokinetics has 103.01 million shares outstanding. The number of shares has increased by 7.46% in one year.

Shares Outstanding 103.01M
Shares Change (YoY) +7.46%
Shares Change (QoQ) +3.15%
Owned by Insiders (%) 0.88%
Owned by Institutions (%) 113.77%
Float 102.08M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 976.84
Forward PS 1,885.85
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 995.56
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.12

Current Ratio 6.12
Quick Ratio 6.00
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -17.59

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -65.10%
Return on Capital (ROIC) -134.31%
Revenue Per Employee $17,801
Profits Per Employee -$1.24M
Employee Count 423
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +100.43% in the last 52 weeks. The beta is 0.69, so Cytokinetics's price volatility has been lower than the market average.

Beta (1Y) 0.69
52-Week Price Change +100.43%
50-Day Moving Average 74.32
200-Day Moving Average 47.74
Relative Strength Index (RSI) 51.02
Average Volume (30 Days) 3,584,036

Short Selling Information

The latest short interest is 14.80 million, so 14.37% of the outstanding shares have been sold short.

Short Interest 14.80M
Short Previous Month 14.53M
Short % of Shares Out 14.37%
Short % of Float 14.50%
Short Ratio (days to cover) 4.94

Income Statement

In the last 12 months, Cytokinetics had revenue of $7.53 million and -$526.24 million in losses. Loss per share was -$5.45.

Revenue 7.53M
Gross Profit 7.53M
Operating Income -496.21M
Pretax Income -526.24M
Net Income -526.24M
EBITDA -486.05M
EBIT -497.94M
Loss Per Share -$5.45
Full Income Statement

Balance Sheet

The company has $614.82 million in cash and $755.77 million in debt, giving a net cash position of -$140.95 million or -$1.37 per share.

Cash & Cash Equivalents 614.82M
Total Debt 755.77M
Net Cash -140.95M
Net Cash Per Share -$1.37
Equity / Book Value -386.32M
Book Value Per Share -3.75
Working Capital 525.37M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$414.33 million and capital expenditures -$1.42 million, giving a free cash flow of -$415.75 million.

Operating Cash Flow -414.33M
Capital Expenditures -1.42M
Free Cash Flow -415.75M
FCF Per Share -$4.31
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -6,589.71% and -6,988.63%.

Gross Margin 100.00%
Operating Margin -6,589.71%
Pretax Margin -6,988.63%
Profit Margin -6,988.63%
EBITDA Margin -6,454.79%
EBIT Margin -6,612.72%
FCF Margin -5,521.24%

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -7.46%
Shareholder Yield -7.46%
Earnings Yield -7.15%
FCF Yield -5.65%
Dividend Details

Analyst Forecast

The average price target for Cytokinetics is $80.53, which is 14.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target $80.53
Price Target Difference 14.86%
Analyst Consensus Strong Buy
Analyst Count 15
Revenue Growth Forecast (5Y) 185.69%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.

Last Split Date Jun 25, 2013
Split Type Reverse
Split Ratio 1:6

Scores

Cytokinetics has an Altman Z-Score of -1.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.16
Piotroski F-Score 2